Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1645 1646 1651 1671
This examiner grants 51% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19454185 | haNK Cetuximab Combinations And Methods | Final Rejection | NantCell, Inc. |
| 18553042 | VACCINE COMPOSITION AGAINST CORONAVIRUS | Final Rejection | LG CHEM, LTD. |
| 18280863 | BIOMARKERS FOR IDENTIFYING AND TREATING CANCER PATIENTS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18244849 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | Final Rejection | The Regents of the University of California |
| 18035160 | HLA CLASS II-RESTRICTED TCRS AGAINST THE KRAS G12>V ACTIVATING MUTATION | Non-Final OA | The Regents of the University of California |
| 18579142 | T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof | Non-Final OA | Emory University |
| 18478808 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18270808 | A BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 | Non-Final OA | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy